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Abstract
The choice of inotropic agent, particularly in catecholamine-
resistant septic shock, remains an area of debate. Here we discuss
a recent trial examining the use of vasopressin in a carefully
controlled trial setting. Yet more data on the use of drotrecogin alfa
(activated) in septic shock are described, as are novel but as yet
experimental approaches to the treatment of sepsis. Finally, it is
important not to forget to read the latest surviving sepsis
guidelines.
“Man is a creature composed of countless 
millions of cells: a microbe is composed of only one,
yet throughout the ages the two have been in
ceaseless conflict”
AB Christie
Septic shock remains a common cause of death in intensive
care units worldwide and presents the clinician with a variety
of management problems. The Surviving Sepsis Campaign
has gone far in collating the considerable wealth of infor-
mation currently available about this devastating condition
and provides excellent guidelines, which are essential reading
for consultant and trainee alike [1]. However, new insights
into the management of these patients continue to accu-
mulate, and the last few months have been no exception. One
of the basic tenets of treating septic shock is the provision of
cardiovascular support through the use of catecholamines,
although there is much interest in other agents as addressed
in the study by Russell and colleagues in The New England
Journal of Medicine [2]. They examined the use of the
pituitary-derived peptide hormone vasopressin in patients
with septic shock through a multi-centred, randomised trial
involving 778 patients given low-dose vasopressin (0.01 to
0.03 U/min) in addition to noradrenaline (norepinephrine)
compared with noradrenaline alone. No overall differences
were found between the two groups in terms of either the
primary endpoint of 28-day mortality or the various secondary
endpoints. Interestingly, the vasopressin-treated group had a
28-day mortality of 35% compared with 39% of the group
treated with noradrenaline alone, which is clearly much less
than one would expect. The authors do suggest that this may
reflect an improvement in the overall care of patients with
septic shock, but equally it could reflect the selection criteria
used: 6,229 patients were assessed for eligibility but more
than 5,000 patients were not enrolled, a significant propor-
tion of whom had cardiac disease. The authors themselves
do concede that the baseline mean arterial pressures observed
(72 to 73 mmHg) were somewhat higher than expected and
therefore the trial probably reflects the use of vasopressin as
a catecholamine-sparing drug rather than being an evaluation
of vasopressin as an agent in shock unresponsive to
catecholamines. Subgroup analysis on those “thought to be
more severe” (at least 15 μg noradrenaline per minute), on
whom vasopressin might be deemed to have a greater effect,
failed to show any decrease in mortality. What does this
study add to our current clinical practice? It does show that,
in this carefully selected patient cohort, vasopressin use is
safe but does not confer any additional benefit over
catecholamine use. As with many studies, we await the next
randomised controlled trial!
The differences between everyday clinical practice and the
restrictive environs of the randomised controlled trial are
further highlighted in a retrospective observational study by
Wheeler and colleagues on the use of drotrecogin alfa
(activated; DrotAA) [3]. This is an interesting study that
compares DrotAA use in five teaching institutions with that
reported in the Recombinant Human Activated Protein C
Worldwide Evaluation in Severe Sepsis (PROWESS) trial [4]
and demonstrates that in the group observed, which reflects
current practice, patients who received DrotAA were younger,
had more severe illness, increased comorbidities and received
treatment later than those enrolled in the PROWESS study.
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Indeed, nearly 50% of those treated would have been
ineligible for the PROWESS trial principally through delayed
onset of treatment, with 33.9% of patients receiving DrotAA
later than 2 days after the onset of severe sepsis. What is
clear is that those patients receiving early treatment (day 0)
fared similarly in terms of mortality to those in the PROWESS
study despite the disparity in the groups. Those treated later
did not; for example, patients treated at day 0 had a 33%
mortality, whereas those treated at day 2 or later had a 52%
mortality. These results probably strengthen the case for
DrotAA use when applied appropriately and yet again
emphasises the need for the early recognition and treatment
of sepsis.
The evolution of the treatment of our patients with septic
shock requires continuing to search for improvements in out-
come through alternative agents. The future may involve
modulation of the immune response itself. Relatively recently,
the anti-inflammatory role of the vagus nerve has been
explored in an animal model of endotoxaemia and shock, the
so-called ‘cholinergic anti-inflammatory pathway’, and is a
mechanism for the neural inhibition of inflammation through
regulation of the inflammatory response [5,6]. A recent study
by Hofer and colleagues in Critical Care Medicine addresses
this through assessing the role of pharmacological cholin-
esterase inhibition on survival in experimental sepsis [7]. A
murine model of sepsis was employed, namely sepsis
induced through caecal ligation and puncture. Animals were
then treated with intraperitoneal injections of nicotine, physo-
stigmine or lipopolysaccharide-free 0.9% normal saline.
Animals treated with intraperitoneal injections of nicotine
(400 μg/kg), physostigmine (80 μg/kg) and neostigmine
(80 μg/kg) demonstrated improved survival, and treatment
with physostigmine significantly reduced lethality as efficiently
as direct stimulation of the cholinergic anti-inflammatory
pathway with nicotine. Downregulation of the binding activity
of nuclear factor-κB was observed, together with a significant
decrease in the concentrations of the circulating pro-
inflammatory cytokines tumour necrosis factor-α, interleukin-
1β and interleukin-6 as well as a decrease in pulmonary
neutrophil invasion. There was no observed difference in
survival between the groups treated with neostigmine and
physostigmine; interestingly, as in most things, septic delay of
treatment beyond 6 hours negated any positive effects on
survival. So far, studies on the cholinergic inflammatory
pathway remain predominantly experimental in nature. The
last 5 years has seen a small collection of studies that have
demonstrated a potential role for cholinesterase inhibitors
and nicotine in the management of sepsis and improved
outcomes; we await further studies with interest.
Barnato and colleagues present a different slant on sepsis,
performing a retrospective study on the racial variation of
patients with sepsis admitted to hospitals within six US states
[8]. This study demonstrates that the incidence of severe
sepsis in blacks is significantly higher than in whites or
hispanics. The authors have made considerable efforts to
negate the confounding effects of poverty and geography,
although they admit that unmeasured differences in behaviour
may be relevant to their results. However, they do raise the
hypothesis that biological differences in susceptibility may
also have a role. No doubt, with the rising tide of genetic
studies, further information is not too far away.
Finally we return to the Surviving Sepsis Campaign guide-
lines, which ‘recommend the protocolized resuscitation of a
patient with sepsis-induced shock … this protocol should be
initiated as soon as hypoperfusion is recognized and should
not be delayed pending ICU admission’. The studies
highlighted here all reinforce the need for the prompt
recognition and early treatment of sepsis. Adherence to these
guidelines may have more of an impact on the outcome of our
patients than any new, as yet unproven, treatments.
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